Efficacy and safety of LB03002, a once-weekly sustained-release human GH for 12-month treatment in Korean children with GH deficiency

Jin Soon Hwang, Hae Sang Lee, Woo Yeong Chung, Heon Seok Han, Dong Kyu Jin, Ho Seong Kim, Cheol Woo Ko, Byung Churl Lee, Dae Yeol Lee, Kee Hyoung Lee, Jeh Hoon Shin, Byung Kyu Suh, Han Wook Yoo, Hyi Jeong Ji, Jin Hwa Lee, Yoon Ju Bae, Duk Hee Kim, Sei Won Yang

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: The purpose of this study was to investigate the efficacy and safety of LB03002, a sustainedrelease human GH (SR-hGH), compared with that of daily rhGH for 12 months in children with GH deficiency (GHD). Methods: A total of 73 children with GHD were screened and 63 eligible subjects were randomized in a 1:1 ratio of LB03002 (SR-hGH) to daily rhGH treatment group. LB03002 was administered once weekly at a dose of 0.5 mg/kg while daily rhGH was administered for 6 consecutive days with equally divided doses to make a total of 0.21 mg/kg per week. Treatments were given for 12 months by s.c. injections. Injection site reactions and adverse events were investigated throughout the study period. Results: The mean (S.D.) height velocity (HV) showed a clinically significant increase after the 6-month treatment: 3.00 (1.15) cm/year at screening to 9.78 (1.98) cm/year at 6 months in the LB03002 group; 2.39 (1.63) cm/year at screening to 10.56 (2.65) cm/year at 6 months in the daily rhGH group. The increased HVat 12 months was still maintained in both the groups: 9.06 (1.63) cm/year at 12 months in the LB03002 group; 9.72 (2.32) cm/year at 12 months in the daily rhGH group. Most of the adverse drug reactions were mild and tolerable. No subjects were withdrawn due to adverse events. Conclusion: Weekly injection of LB03002 at a dose of 0.5 mg/kg per week was confirmed to have comparable efficacy to daily injection of rhGH at a dose of 0.21 mg/kg per week. Both formulations were well tolerated.

Original languageEnglish
Pages (from-to)179-185
Number of pages7
JournalEuropean Journal of Endocrinology
Volume169
Issue number2
DOIs
Publication statusPublished - 2013 Aug 1

    Fingerprint

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Hwang, J. S., Lee, H. S., Chung, W. Y., Han, H. S., Jin, D. K., Kim, H. S., Ko, C. W., Lee, B. C., Lee, D. Y., Lee, K. H., Shin, J. H., Suh, B. K., Yoo, H. W., Ji, H. J., Lee, J. H., Bae, Y. J., Kim, D. H., & Yang, S. W. (2013). Efficacy and safety of LB03002, a once-weekly sustained-release human GH for 12-month treatment in Korean children with GH deficiency. European Journal of Endocrinology, 169(2), 179-185. https://doi.org/10.1530/EJE-13-0148